









p16INK4A-expressing mesenchymal stromal cells restore the 
senescence–clearance–regeneration sequence that is impaired in 























Resource Version Publisher Version 
p16INK4A-expressing mesenchymal stromal cells restore the senescence–
clearance–regeneration sequence that is impaired in chronic
muscle inflammation
Takako S. Chikenji ⁎, Yuki Saito, Naoto Konari, Masako Nakano, Yuka Mizue, Miho Otani, Mineko Fujimiya
Department of Anatomy, Sapporo Medical University School of Medicine, Sapporo, Hokkaido 060-8556, Japan
a b s t r a c ta r t i c l e i n f o
Article history:
Received 4 January 2019
Received in revised form 28 April 2019
Accepted 6 May 2019
Available online 23 May 2019
Background: The therapeutic benefits of mesenchymal stromal cells (MSCs) include treatment of chronic inflam-
mation. However, given the short-lived engraftment of these cells in vivo, their therapeutic efficacy remainsmys-
terious. Transient induction of cellular senescence contributes to activation of immune cells, which promotes
clearance of damaged cells during tissue remodelling. Thismay occur in tissue-residentmesenchymal progenitor
cells during regeneration. Elucidation of the role of senescence in tissue-resident mesenchymal progenitor cells
during regeneration would provide insight into the profile of therapeutic MSCs for treatment of chronic inflam-
matory disease.
Methods:We evaluatedmultipotent mesenchymal progenitor cells, termed fibro/adipogenic progenitors (FAPs),
and immune cells in acute muscle injury (AMI) model mice and mice with myosin-induced experimental auto-
immune myositis, a model of chronic inflammatory myopathy (CIM). Human bone marrow MSCs were
optimised for the treatment of CIM using placental extract.
Finding: FAPs in AMI transiently expressed p16INK4A on days 1 and 2 after injury and recruited phagocytic im-
mune cells, whereas in CIM, p16INK4A expression in FAPs was low. Cellular senescence occurs during the natural
maturation of the placenta. Therefore, we used human placental extract to induce p16INK4A expression in thera-
peutic human bonemarrowMSCs in culture. Treatment of CIMwith p16INK4A-expressingMSCs promoted tissue
remodelling by transiently increasing the abundance of engrafted MSCs, inducing cellular senescence in innate
FAPs, and recruiting phagocytic immune cells.
Interpretation: MSCs may exert their effect by remodelling the chronic inflammatory environment via
senescence-related regenerative processes.









Mesenchymal stromal cells (MSCs) have attracted a great deal of at-
tention as a novel therapeutic for use against multiple chronic inflam-
matory diseases. Due to their potent immunosuppressive and anti-
inflammatory activities, availability, and genomic stability during
in vitro expansion, therapies based on these cells have been rapidly
brought to clinical trials, and the number of such trials increases yearly
[1]. However, the lack of provenmechanisms and plausible explanatory
hypotheses for the benefits conferred byMSCs can no longer be ignored
by researchers seeking to develop safe and effective therapies [2]. Sev-
eral biomarkers, including tumour necrosis factor (TNF)–stimulated
gene 6 protein (TSG-6) and indoleamine 2,3-dioxygenase (IDO) [3],
have been reported as markers of MSC function; however, it is widely
believed that MSCs are not solely responsible for immunomodulation,
and that other cells such as macrophages or regulatory T cells are also
involved in immunosuppressive activities [4,5]. In addition, the
supporting evidence for MSC efficacy has beenmet with skepticism be-
cause of the short-lived engraftment of MSCs in vivo [2].
In a demonstration of the efficacy of short-lived MSC engraftment,
Galleu et al. reported that MSCs are induced to undergo perforin-
dependent apoptosis by recipient cytotoxic cells, and that this process
is important for initiation of MSC-induced immunosuppression [6].
Cell death is a crucial step for tissue regeneration during inflammation
[7]. Inmuscle regeneration, apoptosis ofmultipotentmesenchymal pro-
genitor cells, termed fibro/adipogenic progenitors (FAPs), is required
during the remodelling process associated with acute inflammation,
and increases survival of FAPs due to failure of apoptosis, which results
in muscle fibrosis [8]. However, the regulatory mechanisms that govern
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these properties of MSCs, specifically in regard to their ability to modify
tissue homeostasis and inflammation by producing various cytokines
and growth factors, remain unknown.
Cellular senescence is another mechanism that leads to cell elim-
ination. In contrast to cells that undergo apoptosis, senescent cells
enter a cell-cycle arrest and persist in the tissue. Subsequently, they
influence neighbouring cells by secreting soluble factors, a response
collectively known as the senescence-associated secretory phenotype
(SASP), which activates immune cells to promote clearance of cell
debris during tissue remodelling [9]. The importance of senescent
cells is highlighted by the fact that cellular clearance and interference
with the phagocyte switch from an inflammatory to a pro-
regenerative phenotype have positive effects on the outcome of tis-
sue regeneration [9,10].
The tumour suppressor proteins p16INK4A and p14/p19ARF, which are
encoded by the CDKN2A locus, are often transcriptionally activated in
cells undergoing senescence; moreover, these factors are major regula-
tors of the senescence program [11]. Although p16INK4A expression in-
creases with age or chronic inflammation/fibrosis, and is a robust
senescence marker in multiple human and mouse tissues [12,13],
p16INK4A-expressing cells also play essential roles in wound healing
[14,15] and suppression of liver fibrosis in adults [10]. Senescent cells
have acute beneficial roles when present during repair or in the context
of cancer, but their chronic effects include promotion of tumour pro-
gression and contribute to the pathology of age-related diseases [16].
That is, the breakdown of normal senescencemechanisms that promote
tissue remodelling worsens the deleterious effects of these cells in
chronic inflammatory pathogenesis, suggesting that targeting senescent
cells is a therapeutic option for ameliorating disease progression or
chronic inflammation.
Idiopathic inflammatory myopathies are rare, heterogeneous, au-
toimmune diseases characterised by muscle weakness, inflammation,
and fibrosis [17]. The pathogenic mechanism of these myopathies is
unknown, but autoimmune processes are strongly implicated [17].
We hypothesise that (1) if breakdown of the senescence mechanism
underlies the pathogenesis of chronic inflammatory myopathies, it
could result in accumulation of heterogeneous cell types, specifically
in chronic inflammation but not in acute inflammation; and (2) if
cellular senescence is observed in acute inflammation, it may pro-
mote regenerative inflammation in chronic inflammatory
myopathies.
In this study, we observed transient, high-level expression of
p16INK4A in FAPs in the early phase of a mouse model of acute in-
flammatory injury. FAPs promoted immune cell infiltration with dis-
tinct temporal and spatial kinetics over the course of muscle
regeneration. By contrast, these cellular dynamics broke down in a
mouse model of chronic inflammatory myopathy, in which FAPs
expressed low levels of p16INK4A. The inherent cellular senescence
mechanism of mesenchymal cells, which promote muscle regenera-
tion, may explain the efficacy of MSC therapy against chronic inflam-
matory disease. Furthermore, we developed p16INK4A-expressing
MSCs as a supplemental therapy for chronic inflammatory myopathy.
This approach increased therapeutic efficacy by inducing FAP senes-
cence and orchestrating immune cellular dynamics by recruiting
macrophages, neutrophils, and natural killer (NK) cells, which collec-
tively constitute the regenerative environment of acute muscle injury
in chronic inflammatory myopathy.
2. Materials and methods
2.1. Animals
Miceweremaintained in a specific pathogen–free facility. All animal
care and experiments were performed in accordancewith protocols ap-
proved by the Ethics Committee of the Animal Experimentation Center
of the Sapporo Medical University School of Medicine. Female BALB/c
mice (N6 weeks of age; Sankyo Lab Service, Tokyo, Japan) were used
in the experiments.
2.2. Muscle injury model
Isofluranewas used to anesthetise themice. The acutemuscle injury
(AMI) model was created by injecting 50 μl of 1.2% barium chloride
(Sigma-Aldrich, St. Louis, MO, USA) diluted in sterile distilled water
into the triceps surae as previously described [18]. The chronic inflam-
matory myopathy (CIM) model used to study autoimmune myopathy
was created by immunisingmicewith partially purifiedmyosin, includ-
ing myosin-binding protein C. The myosin was partially purified as re-
ported previously [19], with slight modifications. Briefly, skeletal
muscle obtained from 8 to 10-week-old BALB/c mice was stored at
−80 °C until use. Thawed and minced muscle (30 g) was washed four
times in 0.03 M KCl/0.15 M sodium phosphate buffer (pH 7.5), 1 mM
EDTA, and 1mMDTT. Myosin was extracted by incubation of 30 gmus-
cle with 90 ml chilled 0.3 M KCl/0.15 M phosphate buffer containing
5 mM MgCl2, 5 mM ATP, 1 mM DTT, and 1 mM EDTA on ice for
45 min with constant agitation. The homogenate was centrifuged for
30 min at 4 °C at 2200g. For myosin precipitation, the supernatant was
collected, filtered, and diluted with 15 volumes of chilled ultrapure
water. The precipitate was recovered via centrifugation for 10 min at 4
°C at 10,000g, dissolved in 0.5 M KCl, and stored at −80 °C. BALB/c
mice (8 weeks old) were each immunised three times, at 1-week inter-
vals, with 200 μl of an emulsion containing 1 mg myosin with 100 μg
complete Freund's adjuvant (Chondrex Inc., Redmond, WA, USA),
which was injected bilaterally into the hock (first immunisation) [20],
tail base (second immunisation), and flank (third immunisation). One
hour after the first immunisation, pertussis toxin (500 ng in 100 μl sa-
line; List Biological Laboratories, Campbell, CA, USA) was intraperitone-
ally injected into each animal.
2.3. Cell preparation and flow cytometry
Triceps surae muscles were carefully dissected to remove attached
fat tissue, blood vessels, tendons, and nerves. Muscles were dissociated
Research in context
Evidence before this study
The therapeutic benefits ofmesenchymal stromal cells (MSCs) are
well documented, but given the short-lived engraftment of these
cells in vivo, currently no plausible hypotheses can explain their
therapeutic efficacy. Transient induction of cellular senescence
contributes to cell clearance, followed by tissue remodelling.
Added value of this study
Here, we show that placental extracts induced p16INK4A expres-
sion in therapeutic MSCs. Cellular senescence occurs during the
natural maturation program of the placenta. Treatment of chronic
inflammatory myopathy (CIM) mice with p16INK4A-expressing
MSCs promoted tissue remodelling by transiently increasing the
abundance of engrafted MSCs, inducing cellular senescence in in-
nate fibro/adipogenic progenitors (FAPs), and recruiting phago-
cytic immune cells. This phenomenon was similar to the
endogenous regeneration process after acute damage to skeletal
muscle.
Implications of all the available evidence
MSCs may exert their effect by remodelling the chronic inflamma-
tory environment via senescence-related regenerative processes.
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mechanically and digested for 60min at 37 °C in PBS containing 2.5mM
CaCl2 and 0.2% collagenase type 2 (Worthington Biochemical Corpora-
tion, Lakewood, NJ, USA). The muscle tissue was passed several times
through an 18-gauge needle and digested for 30min at 37 °C. The resul-
tant muscle slurries were filtered twice, first through a 100-μm cell
strainer (EASYstrainer™ Cell, Greiner Bio-One, Kremsmuenster,
Austria) and then through a 40-μm cell strainer (Greiner Bio-One).
Erythrocytes were removed by treatment of the sample with RBC lysis
solution (QIAGEN, Hilden, Germany). The isolated cells were stained
for 15 min in Zombie Violet™ Dye (BioLegend, San Diego, CA, USA) di-
luted 1:100 in PBS, washed, and then fixed and permeabilised with
the PerFix-nc Kit (Beckman Coulter, Brea, CA, USA) for detection of in-
tracellular antigen. Antibody concentrations and sources are shown in
Supplementary Table 1. Negative controls were stained with isotype
control or secondary antibody only. Flow cytometry analysis was per-
formed on a FACSCanto™ II system (BD Biosciences, Franklin Lakes, NJ,
USA) equipped with 405-, 488-, and 633-nm lasers. The FACSDiva™
(BD Biosciences) and Kaluza V1.5a (Beckman Coulter) software were
used to collect and analyse the data. A representative example of iden-
tification of dead cells with Zombie Violet™ Dye and gating strategies
is depicted in Fig. S1.
2.4. Ethics statement
The ethical committees of SapporoMedical University approved this
study (Reference number, 262–110, 302–1134). Human placenta and
bone marrow samples were collected after written informed consent
was obtained from all donors.
2.5. Human mesenchymal stromal cells (MSCs) and placental extract (PE)
preparations
Heparinised bonemarrow (10ml) was aspirated from the iliac crest
during total hip arthroplasty procedures. All donors were diagnosed
with osteoarthritis of the hip joint. Each sample was centrifuged at
300g for 10 min. The cell fraction was isolated and suspended in an
amount of complete medium (Dulbecco's modified Eagle's medium
[DMEM; Sigma-Aldrich], containing 4500mg/l glucose, 10% fetal bovine
serum [FBS], and 1% penicillin–streptomycin)) equal in volume to the
originally aspirated bone marrow. Suspended bone marrow cells
(1 ml) were plated in a 100-mm polystyrene culture dish in 9 ml of
complete medium. Cultures were maintained at 37 °C in a humidified
atmosphere containing 5% CO2. Nonadherent cells were removed after
1 week of adhesion, and the culture medium was replaced twice a
week. MSCs were harvested as passage 0 after 3–4 weeks of culture.
After trypsinisation, 4 × 105 MSCs were seeded in 100-mm polystyrene
culture dishes in 9 ml of complete medium (passage 1). At passage 2,
MSCswere culturedwith completemedium (MSCs) ormedium supple-
mented with PE (MSCs+PE) in vitro during 48–72 h. Continuous culti-
vation (CC) of MSCs was performed from passages 6 to 11. MSC and
MSC + PE samples were labelled with PKH26 (Sigma-Aldrich) before
treatment in vivo. Then, 1 × 105 PKH-labelled MSCs or MSCs+PE were
suspended in 25 μl PBS and locally injected into the triceps surae of
each leg. Cells were tested for mycoplasma using the e-Myco™ Myco-
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Fig. 1. Activation of pro-inflammatory and phagocytic cells is impaired in chronic inflammatory myopathy. (a) Schematic diagram of procedures for generating the acute muscle injury
(AMI) and chronic inflammatory myopathy (CIM) models. (b) Representative CD11b, F4/80, and Ly6C counter plots for CIM and AMI (1, 2, and 5 days after injury). (c and
d) Percentages of CD11b + F4/80+ macrophages (c), CD11b + F4/80 Ly6Clow anti-inflammatory macrophages (d), and CD11b + F4/80 Ly6Chi pro-inflammatory macrophages (d).
(e) Representative CD11b and CD49b counter plot in CIM and AMI (1, 2, and 5 days after injury). (f) Percentage of CD11b + CD49b NK cells. Quantitative data are shown as means ±
SEM with dot plots. P-values were determined by one-way ANOVA adjusted by Tukey's method. (*P b .05, **P b .001).
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After removal of RBCs from minced placental tissue, the tissue was
suspended in serum-free medium and shaken for 48–72 h at 4 °C.
After centrifugation, supernatants of tissue suspensions were obtained
as PE. Protein concentrations were determined using a BCA assay kit
(Thermo Fisher Scientific, Waltham, MA, USA).
2.6. Histology and immunofluorescence
Triceps surae muscles were frozen in liquid nitrogen–cooled
isopentane and stored at −80 °C until analysis. Cryosections (8 μm
thick) obtained on a cryostat were air-dried, fixed in 4% paraformalde-
hyde, washed in PBS, and either stained with hematoxylin & eosin or
immunostained. For immunostaining, tissue sections were incubated
in 0.3% Triton-X/0.01 M PBS (PBS-T) and incubated with 2% bovine
serum albumin for 60 min at room temperature (RT). After 0.01 M
PBS-T washes, the sections were incubated at 4 °C overnight with pri-
mary antibodies, and thenwith secondary antibodies. Antibody concen-
trations and sources are shown in Supplementary Table 1.
For immunohistochemistry of cultured cells, the cellswere grownon
8-well Lab-Tek™ chamber slides (Thermo Scientific™ Nunc™; Thermo
Fisher Scientific). The cultured cells were fixed in 4% paraformaldehyde
for 15min at RT, washed in PBS-T, and incubated with 2% bovine serum
albumin for 60 min at RT. After PBS-T washes, the cells were incubated
at 4 °C overnight with primary antibodies, followed by secondary anti-
body staining. Antibody concentrations and sources are shown in Sup-
plementary Table 1. Secondary antibodies were coupled to
fluorochromes (Cyanine Dye 3, Alexa Fluor 488, or Alexa Fluor 647),
and nuclei were stained with 1:1000 4′,6-diamidino-2-phenylindole
(DAPI) (D523, Dojindo, Kumamoto, Japan). After further washes, tissue
sections were mounted in VECTASHIELD (Vector Laboratories, Burlin-
game, CA, USA). Sections were examined under a confocal laser scan-
ning microscope (Nikon/A1; Nikon, Tokyo, Japan).
2.7. SA-β-gal assay
SA-β-gal assays were conducted using the Senescence Detection Kit
(BioVision, Inc., Milpitas, CA, USA). Briefly, cells were cultured on 8-well
chamber slides for 48 hwith orwithout PE. Cultured cells were fixed for
15 min at RT in 4% paraformaldehyde and then incubated overnight at
37 °C in SA-β-gal buffer. After washes, the cells were analysed under a
microscope.
2.8. Cell proliferation assay
MSCs and MSCs+PE were cultured on 96-well culture plates at a
concentration of 2 × 103 cells per well in DMEM supplemented with
10% FBS and 1% penicillin/streptomycin. After culturing for 24 h and
72 h, a cell proliferation assay was performed using the Cell Counting
Kit-8 (Dojindo).
2.9. Co-Culture of MSCs with Macrophages
MSCs andMSCs+PEwere labelledwith PKH26 (Sigma-Aldrich), and
RAW264.7 macrophages were labelled with PKH2 (Sigma-Aldrich). Co-
Fig. 2. PDGFRα-positive fibro-adipogenic progenitors (FAPs) express high levels of p16INK4A in acute muscle injury. (a and b) Flow cytometry analysis of CD11b, F4/80, and p16INK4A, and
percentages of CD11b+ F4/80+ p16INK4A+ cells in both AMI and CIM (n=3 per group). (c) Representative image of F4/80- and p16INK4A- immunostained triceps surae in CIM and AMI
(1, 2, and 5 days after injury). (d and e) Representative image of hematoxylin and eosin (H&E) staining and PDGFRα- and p16INK4A- immunostained triceps surae in CIM and AMI (1, 2, and
5 days after injury) and Control (d), and percentage of p16INK4A+ FAPs in randomly chosen fields of view (n=3–4 per group) (e). Quantitative data are shown asmeans±SEM (dot plot).
P-values were determined by one-way ANOVA, adjusted by Tukey's method. (*P b .05, **P b .001).
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culture was performed using a double-chamber co-culture systemwith
a 0.4-μm pore size membrane (12-well insert, BD Biosciences) separat-
ing the upper and lower chamber cells. MSCs (2 × 104 cells/well) were
placed in the upper chamber, and RAW264.7 cells (2× 105 cells/well) in
the lower chamber. The co-cultures were incubated for 24h, and then
MSCs or MSCs+PE cells were collected by trypsinisation. The collected
MSCs (2 × 104 cells/well) were co-cultured above the RAW264.7 mac-
rophages in complete medium for 48 h. Cells were tested for myco-
plasma using the e-Myco™ Mycoplasma PCR Detection Kit (iNtRON
Biotechnology, Inc., Seongnam-si, South Korea). After trypsinisation,
cells were collected and analysed on a FACSCanto™ II (BD Biosciences),
equipped with 488-nm and 633-nm lasers, to detect double-positive
staining. Data collection and analysis were conducted using FACSDiva™
(BD Biosciences) and Kaluza V1.5a (Beckman Coulter).
2.10. RNA extraction and quantitative real-time PCR
Total RNA, isolated from cultured MSCs using the TRI Reagent®
(Molecular Research Center, Inc., Cincinnati, OH, USA), was reverse-
transcribed into cDNA using the Omniscript RT Kit (205,113;
QIAGEN). Quantitative PCR was performed using Power SYBR®
Green Master Mix (4,368,702; Applied Biosystems, Foster City, CA,
USA) in a 7500 Real-Time PCR System (Applied Biosystems) and
the following conditions: 50 °C for 2 min, 95 °C for 10 min, and 40
amplification cycles comprising 95 °C for 15 s and 60 °C for 1 min.
Expression levels were normalised against the corresponding levels
of GAPDH and 18S rRNA mRNA. The primer sequences used for the
PCR are shown in Supplementary Table 2. Samples were compared
using the ΔΔCt method.
Fig. 3. Placental extract (PE) induces functional senescence in MSCs. (a) Representative image of SA-β-galactosidase in MSCs with or without PE supplementation in vitro. (b–d)
Representative confocal images of MSCs immunostained for OCT4 and p16INK4A with or without PE supplementation in vitro (b), and quantitation of OCT4- and p16INK4A-positive area
(n = 5 per group) (c and d). (e–g) Relative mRNA expression of DNMT1, NANOG, OCT4(POU5F1), SOX2, p14ARF(CDKN2A), p16INK4A(CDKN2A), p21(CDKN1A), p53(TP53), and RB1, and
TERT in MSCs+PE (n = 7 per group). Dashed line indicates mRNA expression in MSCs without PE supplementation. (h) Hierarchical clustering of stemness-, senescence-, and
cytokine-related gene expression in MSCs (n = 8). Red indicates up-regulation and green indicates down-regulation by PE supplementation. (i) Principal component analysis (PCA) of
stemness-, senescence-, and cytokine-related gene expression in MSCs (n = 8), MSCs+PE (n = 8), and continuously cultivated (CC) MSCs (n = 4). (j–o) Representative image of
confocal images of F-actin, Yap, phospho-Yap (p-Yap), and LATS1/2 immunostained MSCs with or without PE supplementation in vitro, and quantitation of F-actin–, Yap-, phospho-
Yap (p-Yap)–, and LATS1/2-positive areas (n = 5 per group). Quantitative data are shown as means ± SEM (dot plot) or means and medians with interquartile range (IQR) and 1.5×
IQR (box-and-whisker plot). P-values were determined by two-tailed Student's t-test. (*P b .05, **P b .001).
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2.11. Array analysis for cytokines
DMEM +10% FBS + PE, and DMEM +10% FBS samples containing
protein and supernatant cytokines from MSC cultures, with or without
PE, were analysed using the Proteome Profiler™ Array Human XL Cyto-
kine Array Kit (ARY022B; R&D Systems, Minneapolis, MN, USA).
2.12. CRISPR knockout in MSCs
CDKN2A knockout was performed using the p14 ARF/p16 CRISPR/
Cas9 KO plasmid (Santa Cruz Biotechnology, Dallas, TX, USA), which in-
cludes green fluorescent protein (GFP) and a pool of three plasmids,
each encoding Cas9 nuclease and a target-specific 20-nt guide RNA de-
signed formaximumknockout efficiency. Onday 1,MSCswere plated in
6-well plates in antibiotic-free growth medium. On day 2, the medium
was replaced with fresh medium, and plasmid DNA and UltraCruz®
transfection reagent complex were added (KO-MSC). The cells were in-
cubated for 72 h at 37 °C, and transfection efficiency was confirmed by
monitoring protein expression of GFP and p16INK4A by confocal laser
scanningmicroscopy (Fig. S2). As a scrambled control, we used the Con-
trol CRISPR/Cas9 plasmid (sc-418,922) (SC-MSC). At passage 2, KO-
MSCs or SC-MSCs were cultured with complete medium supplemented
with PE in vitro. Then, 1 × 104 KO-MSCs or SC-MSCs were suspended in
25 μl PBS and locally injected into the triceps surae of each leg.
2.13. Statistical analysis
No power calculations were performed to determine required sam-
ple sizes. No specific randomisation method was used to determine the
allocation of animals to experimental groups and their treatment. Mice
were only excluded from the study if their health status was compro-
mised, such as when they had visible wounds from fighting. Investiga-
tors were not blinded to allocations during the experiments or at the
outcome assessment, except for behavioural assessments. Quantitative
data are presented as either means ± the standard error of the mean
(SEM) or median with interquartile range (IQR) and 1.5 × IQR. Dot
plots or box-and-whisker plotswere generated using ggplot2, a plotting
system for R based on The Grammar of Graphics (The R Foundation for
Statistical Computing, Vienna, Austria). The R packages FactoMineR and
factoextra were used to generate heat maps, Ward's hierarchical ag-
glomerative clustering, and principal component analyses. The normal-
ity of the datawas checked using the Shapiro-Wilk test. A pairwise t-test
was used for comparisons between two groups. One-way analysis of
variance (ANOVA) was performed to determine differences among
three or more groups. Pairwise comparisons were only performed
when statistical significance was indicated by one-way ANOVA. Tukey's
methodwas used to adjust P-values formultiple comparisons. All statis-
tical analyses were conducted using EZR, a graphical user interface for R
[21]. A two-sided P-value b.05 was considered statistically significant.
Fig. 4.MSCs+ PE exert therapeutic effects on CIMmuscle via immuno-activation. (a) Protocol for treatment of CIMmice usingMSCswith orwithout PE supplementation. (b) Detection of
themacrophage phenotype switch in CIM 1, 2, and 5 days afterMSC treatment. (c-d) Percentage of CD11b+F4/80+ (total)macrophages (c), CD11b+ F4/80+ Ly6Chi pro-inflammatory
macrophages (d), and CD11b + F4/80+ Ly6Clow pro-fibrosis macrophages (d) (n = 4 per group). (e) Representative confocal images of F4/80- and p16INK4A-immunostained triceps
surae in CIM 1, 2, and 3 days after injection of PKH-labelled MSCs. (f–j) Flow cytometry analysis of CD11b and Gr-1 (Neutrophil) (f), and CD11b and CD49 (NK cell) (i), and
quantification following MSC treatment (g, h, and j). (k) Representative confocal images of CD49b- and p16INK4A-immunostained triceps surae in CIM 5 days after injection of PKH-
labelled MSCs. Quantitative data are shown as means ± SEM (dot plot). P-values were determined by one-way ANOVA adjusted by Tukey's method. (*P b .05, **P b .001).
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3. Results
3.1. Breakdown of immune cellular dynamics in chronic inflammatory
myopathy
Acute muscle injury induces an orchestrated inflammatory process
aimed at clearing damaged cells, coordinating the regenerative response,
and restoring tissue homeostasis [22]. However, chronic inflammation
interferes with this orchestration by promoting the accumulation of im-
mune andmesenchymal cells [23], ultimately resulting infibrosis. During
efficient regeneration, granulocytes, monocytes, macrophages, fibro-
blasts, and FAPs transiently increase in number, and then subsequently
become less abundant in order to create space for satellite cells, which
promote myoblast proliferation andmuscle regeneration [22].
Fig. 5.MSCs+ PE induce senescence in resident FAPs and improvemuscle function. (a) Representative image of PDGFRα and p16INK4A staining of PKH-labelledMSC–transplantedmuscle,
1, 2, and 5 days after MSC transplantation. (b and c) Representative image of H&E staining and quantification of the number of regenerating myofibers with central nuclei. (d-f)
Representative image of laminin-immunostained triceps surae in CIM 13 days after MSC transplantation (d), quantification of cross-sectional area of each myofiber (e), and muscle
function as evaluated by hindlimb grip strength test (f). Quantitative data are shown as means ± SEM (dot plot). P-values were determined by two-tailed Student's t-test. (*P b .05,
**P b .001).
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To investigate thedifference in inflammatory cell switchingbetween
acute and chronic muscle inflammation, we used flow cytometry to
measure the time-dependent change in the inflammatory cell popula-
tion. For this purpose, we used two models: barium chloride–induced
acute muscle injury (AMI) model mice [18], and mice with myosin-
induced experimental autoimmune myositis as a model of chronic in-
flammatory myopathy (CIM) [19] (Fig. 1a). AMI model mice, which
are induced by intra-muscular injection of barium chloride, regenerate
muscle tissue over 3–4 weeks after acute inflammation [18]. The CIM
model was created by immunising mice with partially purified myosin,
including myosin-binding protein C, resulting in infiltration of CD8+
and major histocompatibility complex (MHC) class I + cells (Fig. S3),
as also occurs in polymyositis [19]. In AMI, the abundance of CD11b+
F4/80+ Ly6Chi monocytes/macrophages and CD11b+ CD49b+ NK
cells, which are typical pro-inflammatory and phagocytic cells, in-
creased from day 1 to day 2, and then declined rapidly on day 5
(Fig. 1b–f). On the other hand, in CIM, the levels of CD11b+ F4/80+
Ly6Chimonocyte/macrophages and CD11b+ CD49b+NK cells remained
low (Fig. 1b–f). Further, in AMI we observed CD11b+ F4/80+ Ly6Chi
pro-inflammatory monocytes/macrophages switch to CD11b+ F4/80+
Ly6Clow anti-inflammatory monocytes/macrophages, whereas in CIM
the CD11b+ F4/80+ Ly6Clow cells were predominant (Fig. 1b–f). These
results indicated that the absence of pro-inflammatory and phagocytic
cell activation is a hallmark of muscle degeneration in CIM. The switch
from a pro-inflammatory to an anti-inflammatory phenotype is essen-
tial for clearance of cell debris and tissue regeneration [24,25]. Further,
the anti-inflammatory phenotype of macrophages promotes fibroblast
proliferation, which increases deposition of connective tissues [26].
We hypothesise that the failure of macrophages to undergo this pheno-
typic change is one of themechanisms underlyingmuscle degeneration
in chronic inflammation. The numbers of pro-inflammatory monocytes
andmacrophages in CIMwere similar to those in early-stage AMI (days
1 and 2) (Fig. S4), but the abundance of anti-inflammatory monocyte/
macrophages was elevated in CIM to levels comparable to those of
AMI on day 5 (Fig. S4). In other words, in CIM, the balance of inflamma-
tory vs. anti-inflammatorymacrophageswas unregulated in the chronic
inflammatory environment. Therefore, we considered that the propor-
tions of various immune cell populations could provide insight into
the immune cell dynamics during acute and chronic inflammation.
Deficiency in p16INK4A influencesmacrophage polarisation in aman-
ner that inhibits pro-inflammatory signalling by these cells [27]. Hence,
we next investigated whether macrophages express p16INK4A after
Fig. 6. CDKN2A-KOMSCs exert reduced therapeutic effects in CIM. (a) Procedure for generation of CDKN2AKO-MSCs and protocol forMSC treatment. (b and c) Flow cytometry analysis of
GFP+ cells of triceps surae in CIM 1, 2, 5, and 11 days after transplantation of GFP-labelledMSCs (b), and percentage of GFP+ cells (c). (d–f) Flow cytometry analysis of CD11b, F4/80, and
Ly6C (d); quantification following MSC transplantation: percentage of CD11b+ F4/80+ total macrophages (e), CD11b+ F4/80+ Ly6Chi pro-inflammatorymacrophages (f), and CD11b
+ F4/80+ Ly6Clow pro-fibrotic macrophages (f) (n = 3–5 per group). (g and h) Flow cytometry analysis of CD45, CD31, and α7-integrin (g), and quantification 11 days after MSC
transplantation (h) (n = 3–4 per group). (i and j) Representative image of laminin-immunostained triceps surae 11 days after MSC transplantation (i), and quantification of the cross-
sectional area of each myofiber (j). Quantitative data are shown as means ± SEM (dot plot). P-values were determined by two-tailed Student's t-test or one-way ANOVA adjusted by
Tukey's method. (*P b .05, **P b .001).
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muscle injury. Flow cytometry measurements of p16INK4A expression in
CD11b+ F4/80+ macrophages in single-cell suspensions derived from
muscle revealed that the percentage of CD11b+ F4/80+ p16INK4A+
cells was higher in AMI on day 1 than in AMI on day 5 and in CIM
(Fig. 2a and b). Immunohistochemical examination revealed that F4/
80+ macrophages expressed high levels of p16INK4A in AMI on days 1
and 2 (Fig. 2c); however, F4/80-negative interstitial cells expressed
p16INK4A more frequently near F4/80+ macrophages (Fig. 2c).
3.2. Transient senescent FAPs andmacrophages are observed in acute mus-
cle injury
FAPs are typical interstitial cells that act as key regulators of muscle
inflammation by influencing immune cells, including macrophages [8].
Hence, to identifywhich cells undergo cellular senescence in themuscle
interstitial space near macrophages, we investigated whether FAPs ex-
press p16INK4A. Immunohistochemical examination revealed transient
expression of p16INK4A in FAPs marked with platelet-derived growth
factor receptor alpha (PDGFRα) after AMI induction, which gradually
decreased and returned to the pre-induction level by day 5 (Fig. 2d
and e). In CIM mice, p16INK4A expression in PDGFRα+ cells was signifi-
cantly lower than on day 1 of AMI, and HE staining revealed large num-
bers of infiltrating cells and fibrotic regions (Fig. 2d and e). We also
found that theproportion of FAPs thatwere p16INK4A+ (79%)was higher
than the proportion of macrophages that were p16INK4A+ (31%) on day
1 in AMI, suggesting that the PDGFRα+ cells might be the primary cells
that enter senescence under inflammatory conditions.
In summary, during the regenerative inflammation process associ-
ated with AMI, p16INK4A+ senescence occurred strongly in PDGFRα+
cells at the early phase of injury, and the abundance of neighbouring im-
mune cells transiently increased, and then decreased. In CIM, however,
cellular senescence was rare among PDGFRα+ cells, but was still more
prominent than in non-injured muscle. It is possible that if p16INK4A+
expression could be induced in therapeutic MSCs, and these cells
could be subsequently injected into a tissue exhibiting chronic inflam-
mation consisting primarily of p16INK4A-low PDGFRα+ cells, it might
trigger a switch to the regenerative condition.
3.3. Generation of functional senescent mesenchymal stem cells using pla-
cental extract
We hypothesised that senescence of mesenchymal cells could pro-
mote a chronic inflammatory environment that promotes regeneration.
To test this idea, we examined senescent human bone marrow MSCs
conditioned in vitro. In MSCs, cellular senescence upon increasing cul-
ture passage is accompanied by expression of p53, p21, p16INK4A, but
continuously cultivated senescent MSCs lose self-renewal capacity and
multi-lineage differentiation potential in vitro, decreasing their immune
modulation activity and ultimately making them less effective for
treating disease [28,29]. Therefore, we focused on a type of senescence
that occurs in a physiologically programmed manner in adult organ-
isms, in particular in placenta, in which cells undergo functional senes-
cence as part of their natural maturation program [30]. This
physiologically programmed senescence is associated with marked
senescence-associated beta-galactosidase (SA-β-gal) activity and ex-
pression of the DNA damage response (DDR) markers and p16, p21,
and p53 [30].
For these experiments, we first established a process for generating
functional senescent MSCs using placental extract (PE). Proteome
array analysis of PE (Fig. S5) revealed abundant RBP-4 (retinol binding
protein) and DPP-4 (dipeptidyl peptidase 4), both of which can induce
cellular senescence [31]. To determine whether PE could induce
p16INK4A expression in human bone marrow MSCs, we supplemented
MSCs with PE in vitro. p16INK4A expression increased dramatically in
MSCs exposed to 0.1 mg/ml PE in the culture media (Fig. S6); accord-
ingly, we used 0.1 mg/ml PE in our subsequent in vitro experiments.
BothMSCs andMSCs+PE had the capacity to undergo multilineage dif-
ferentiation, expressed MSC surface markers, and exhibited colony-
forming capability (Fig. S7).
Cells positive for SA-β-gal, a well-characterised marker of senes-
cence, were present in PE-treated MSC cultures (MSCs+PE) at passage
2 (Fig. 3a). Immunocytometry revealed that expression of p16INK4A
and OCT4 was higher in the MSC + PE group than in the untreated
donor-matched MSCs (Fig. 3b–d). Transcription of pluripotency genes,
such as OCT4(POU5F1), SOX2, and NANOG, which suppress cell differen-
tiation and maintain self-renewal of MSCs [32,33], were upregulated in
MSCs+PE (Fig. 3e). DNMT1, a major DNA methyltransferase responsi-
ble for maintaining methylation status during DNA replication, is di-
rectly regulated by OCT4 and NANOG [33]; its expression was also
upregulated in MSCs+PE (Fig. 3e). Surprisingly, p16INK4A and p14ARF,
(CDKN2A) also increased mRNA expression in MSCs+PE, whereas ex-
pression of p21(CDKN1A), p53(TP53), and RB1 decreased in MSCs+PE
relative to donor-matched MSCs (Fig. 3f).
Human telomerase reverse transcriptase (TERT) is responsible for
maintaining telomere length [34]. In the absence of TERT, the DNA rep-
lication complex cannot completely copy telomeric DNA; consequently,
the telomeres shorten after each cell division. Cellular senescence and
growth arrest are thought to occurwhen telomeres of oneormore chro-
mosomes reach a critical length [34]. ThemRNA expression of TERTwas
higher in MSCs+PE than in untreated MSCs (Fig. 3g). In situ
hybridisation analysis revealed higher expression of both OCT4 and
CDKN2A in MSCs+PE (Fig. S8), and the levels of TERT and CDKN2A
were also increased (Fig. S8).
Hierarchical cluster analysis of genes that were differentially
expressed in MSCs+PE vs untreated MSCs (Fig. 3h) revealed two
major clusters, suggesting that p14ARF and p16INK4A are upregulated
along with OCT4, SOX2, NANOG, IDO1, TSG-6, and IL-6 (Cluster 1) rather
than p21, RB1, p53, and alpha–smooth muscle actin (α-SMA; ACTA2)
(Cluster 2; Fig. 3h). Principal component analysis showed that the
MSC+PE groupwas located further from the cluster of continuous cul-
tivation (CC) of MSCs (Fig. 3i).α-SMA also indicates anMSC fate associ-
ated with expression of F-actin (also known as stress fibers) mediated
by translocation of YAP/TAZ transcription factors into the nucleus, a
key event in regulation of genes associatedwith self-renewal and differ-
entiation [35]. MSCs+PE decreased expression of F-actin (Fig. 3j
and k) and nuclear localisation of YAP (Fig. 3j and l) while increasing
their levels of phospho-YAP (Fig. 3m and n) and LATS1/2(Fig. 3m and
o). Elevated expression of CD47, a key anti-phagocyticmolecule, enables
various types of cancer cells to evade phagocytosis by macrophages,
thereby limiting programmed cell removal [36,37]. CD47 expression
was reduced in MSCs+PE, as shown in Cluster 2 (Fig. 3h).
3.4. Functional senescent MSCs promote tissue remodelling in chronic in-
flammatory myopathy
In order to assess whether senescent MSC exert therapeutic effects
by promoting the switch from the chronic inflammatory environment
to regenerative acute inflammation, we transplanted senescent MSCs
treated with PE, donor-matched MSCs, or PBS (vehicle control) into tri-
ceps surae of CIMmice (Fig. 4a). One day post-MSC transplantation, the
percentage of CD11b+ F4/80+ macrophages did not differ among the
three groups, whereas after 5 days the percentage of CD11b+ F4/80+
macrophages was higher in the MSC + PE group than in the MSC and
vehicle groups (Fig. 4b and c). Furthermore, we could identify different
patterns of macrophage phenotypes: the MSC and vehicle groups were
enriched in anti-inflammatory CD11b+ F4/80+ Ly6Clow macrophages,
whereas the MSC + PE group was enriched in pro-inflammatory
CD11b+ F4/80+ Ly6Chi macrophages 5 days post-transplantation
(Fig. 4b and d). Interestingly, F4/80+ macrophages accumulated close
to p16INK4A+ cells (Fig. 4e). Furthermore, the abundance of CD11b+
Gr-1hi neutrophils transiently increased at 2 days post-transplantation
only in the MSC + PE group (Fig. 4f and g), and CD11b+ Gr-1low
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immature myeloid cells [38] were more abundant in MSCs+PE than in
the vehicle control (Fig. 4f and h). We also examined CD11b+ CD49b+
NK cells by flow cytometry at 5 days post-transplantation. The MSC
+ PE group had a higher percentage of NK cells than the vehicle and
MSC groups (Fig. 4i and j), and CD49b+ NK cells accumulated near
p16INK4A+ cells in the MSC + PE group (Fig. 4k).
To determine whether p16INK4A-expressing MSCs induce a regener-
ative inflammatory condition, we performed immunohistochemical
staining for PDGFRα and p16INK4A in PKH-labelled transplanted MSCs.
p16INK4A-expressing PDGFRα+ FAPs were localised near PKH-labelled
MSCs+PE on days 1 and 2 post–MSC transplantation (Fig. 5a). Interest-
ingly, the PKH-labelled MSCs+PE did not express p16INK4A on day 2,
whereas PKH-labelled MSC cells did (Fig. 5a). These results raised the
possibility that p16INK4A-expressing MSCs+PE could re-enter the cell
cycle by downregulating p16INK4A. To explore this idea, we passaged
MSCs and MSCs+PE in normal media, and then subjected them to cell
proliferation assays. MSCs+PE exhibited greater proliferative ability
than MSCs (Fig. S9). At 5 days post- transplantation, PKH-labelled
MSCs were not observed in any group, but high levels of p16INK4A+
PDGFRα+ FAPs were observed only in MSCs+PE (Fig. 5a). In these
mice, serial sections revealed infiltration of the transplanted area by
macrophages and NK cells (Fig. 5a and Fig. 4e and k). In addition, we
evaluated regeneration of myofibers, and observed that the central nu-
clei and cross-sectional area of each myofiber were improved in the
MSC + PE group relative to the vehicle and MSC groups (Fig. 5b–5e).
Moreover, hind limb grip strength (an indicator of muscle function)
was greater in MSC + PE–transplanted muscle at 13 days post-
transplantation (Fig. 5f).
These results raised the possibility that transplanted MSCs+PE
could induce senescence in FAPs and promote muscle remodelling. To
explore this idea, we performed proteome array analysis to determine
which cytokines were secreted from MSCs+PE (Fig. S10). Levels of
DPP-4, a surface protein that is abundant in senescent cells and enables
their preferential elimination [31], and SerpinE1 (plasminogen activator
inhibitor 1[PAI-1]), a major component of the SASP [39], were elevated
inMSCs+PE (Fig. S10).We then sought to determinewhether SASP fac-
tors secreted by MSCs+PE induced FAPs senescence. To this end, we
cultured FAPs with culture supernatant of MSCs+PE. In-cell ELISA anal-
ysis revealed that factors secreted by MSCs+PE promoted p16INK4A ex-
pression in FAPs; in addition, the DPP-4 inhibitor vildagliptin and
neutralising antibodies against SerpinE1 (PAI-1) decreased p16INK4A ex-
pression of FAPs (Fig. S11). YKL-40 (chitinase 3-like-1 [CHI3L1]) was
also upregulated by MSCs+PE supernatant. YKL-40 up-regulates two
pro-inflammatorymediators, C-chemokine ligand 2 (CCL2) and chemo-
kine CX motif ligand 2 (CXCL2), which promote remodelling in acute
skeletal muscle injury [40]; both of these proteins were also upregu-
lated in MSCs+PE (Fig. S10).
Further, to determine whether senescent MSCs+PE were phagocy-
tosed more often than MSC, we performed phagocytosis assays by co-
culturing MSCs+PE or MSCs with RAW264.7 cells in vitro. MSCs and
MSCs+PE were labelled using PKH26, and RAW264.7 macrophages
were labelled with PKH2. Co-culture was performed in complete me-
dium for a total of 72 h. Cells engulfing PKH26-positive cells were iden-
tified as PKH2-labelled RAW264.7 macrophages, and the percentage of
PKH2+ PKH26+ cells increased in coculture of MSCs+PE and
RAW264.7 macrophages, suggesting that phagocytosis wasmore active
in the MSC + PE cultures (Fig. S12).
3.5. CDKN2A expression in MSCs is required to induce regenerative inflam-
mation for treatment of chronic inflammatory myopathy
We next sought to determine whether expression of CDKN2A (the
locus that encodes INK4A and ARF) [41] in MSCs treated with PE
would influence the therapeutic effects of these cells. Using the
CRISPR/Cas9 system, we created GFP-labelled CDKN2A knockout (KO)
or scrambled control (SC) MSCs, incubated them in PE-containing
media (Fig. S2), and transplanted the cells into the triceps surae of
CIM mice (Fig. 6a). The proportions of GFP+ engrafted cells were 3.2%
(KO-MSC) and 2.2% (SC-MSC) at 1 day after transplantation, but the
abundance of SC-MSCs increased transiently at 2 days after transplanta-
tion (to 10%), and subsequently decreasedwith time (Fig. 6b and c).We
observed an increase in CD11b+ Gr-1hi neutrophils at day 2 after SC-
MSC transplantation, followed by a decrease on day 5; by contrast, in
the KO-MSC transplantation, no increase in neutrophil abundance was
observed at any time point (Fig. S13). The abundance of CD11b+ Gr-
1low monocytes also increased at day 1 after SC-MSC transplantation
and decreased on day 2. By contrast, in the KO-MSC transplantation,
no increase in CD11b+ Gr-1low monocytes was observed at any time
point (Fig. S13). The abundance of CD11b+ F4/80+ macrophages in-
creased on day 1 after SC-MSC transplantation and decreased by day
11, and we could detect cellular switching from CD11b+ F4/80+
Ly6Chi pro-inflammatory macrophages to CD11b+ F4/80+ Ly6Clow
anti-inflammatory macrophages at this time point (Fig. 6d–6f). By con-
trast, KO-MSC–transplanted muscle predominantly contained anti-
inflammatory macrophages and lacked cells in the inflammatory
phase (Fig. 6d–6f). The percentage of CD45-CD31-Integrinα7+ satellite
cells was smaller in KO-MSC–transplanted than in SC-MSC–
transplanted muscle (Fig. 6g and h), and KO-MSC had a comparatively
weak therapeutic effect on muscle cross-sectional area (Fig. 6i and j).
4. Discussion
Despite thewidespread clinical use ofMSCs, their therapeuticmech-
anism remains largely unresolved, and this gap in our knowledge may
explain why the results of clinical trials using these cells have often
been controversial. Here, we showed that p16INK4A-expressing MSCs
promote regenerative processes in chronic inflammatory myopathy by
inducing infiltration of immune cells, especially phagocytes, with dis-
tinct temporal and spatial kinetics over the course of inflammation.
The therapeutic efficacy of senescentMSCsmay explain the paradoxical
observation that MSCs are therapeutically efficacious despite their lack
of engraftment.
Cellular senescence, which is induced by a complex stress response,
causes cells that are capable of proliferating to lose this ability in many
biological and pathological settings [39]. The senescence response is im-
plicated in two apparently disparate processes: tumour suppression
and chronic inflammation/fibrosis. Several lines of evidence indicate
that oncogene-induced senescence functions as a tumourigenesis bar-
rier during early stages of tumourigenesis [42]. In addition, cellular se-
nescence also limits the fibrogenic response to tissue damage by
facilitating the clearance of senescent cells by phagocytosis [10]. Re-
moval of senescent cells attenuates the development of fibrosis and cre-
ates a pro-regenerative environment [39]. We demonstrated that in
contrast to normal tissue, senescent FAPs were less abundant in chronic
inflammation than in acute inflammation, and that local injection of
p16INK4A-hi MSCs into CIM mice promotes FAP senescence and infiltra-
tion of immune cells with a phagocytotic phenotype that induces regen-
erative inflammation. Anti-senescent therapeutics, termed senolytics,
already exist [43]. Both anti-senescence therapy and our pro-
senescence therapy aim to deplete senescent cells with the goal of
promoting regeneration. Pro-senescence therapy could cause potent se-
nescence in a chronic inflammatory environment, like the remodelling
process of acute inflammation, which induces the tissue's innate repair
process.
Recent studies have identified a beneficial effect of senescent cells,
especially p16INK4A-expressing cells [10,15,44,45]. p16INK4A prevents
cell cycle progression from G1 to S phase by inhibiting two cycle-
dependent kinases, CDK4 and CDK6 [46]. p16INK4A-positive fibroblasts
and endothelial cells appear very early in response to a cutaneous
wound [15] and accelerate cutaneous wound healing via induction of
CYR61 (cysteine-rich protein 61) [14]. In the liver, cellular senescence
limits the extent of fibrosis following liver damage, facilitating clearance
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of senescent cells by NK cells [10]; moreover, CDKN2A induced bymus-
cle damage positively correlates with in vivo reprogramming mediated
by IL-6, a major component of the SASP [45]. Our data support the
idea that cellular senescence, especially p16INK4A, promotes remodelling
after injury. Intriguingly, in this study, p16INK4A-expressing FAPs were
more abundant 1 or 2 days after transplantation of MSCs+PE, and
most of these cells were located near engrafted MSCs. This process, me-
diated by paracrine transmission of cellular senescence, has been
termed “bystander senescence” [47,48]. In addition, p16INK4A-
expressing FAPs were present in regions where engrafted MSCs did
not exist 5 days after transplantation of MSCs+PE, suggesting that
bystander senescence might have spread after the transplanted
MSCs were eliminated. We found that the senescence-related factor
DPP-4 was secreted into the culture supernatant at higher levels by
MSCs+PE than by non-treated MSCs. DPP-4 (also known as CD26)
is much more abundant in senescent cells, and selective expression
of DPP-4 on the surface of senescent cells promotes their preferential
elimination by NK cells [31]. DPP-4 is likely to be only one of the fac-
tors present in PE, but it clearly has the ability to induce senescence
in MSCs.
A major impact of our study is the identification of an effective MSC
subpopulation, based on the remodellingmechanism of chronic inflam-
matory myopathy. Although induction of p16INK4A-hi MSCs is important
for therapeutic activity, functional senescence may be distinct from se-
nescence that occurs due to continuous cultivation, UV exposure, oxida-
tive stress, or heat shock [29]. Indeed, p16INK4A in MSCs is also
upregulated by long-term culture or other culture conditions. In such
cases, the cells typically become enlarged and flattened, and downregu-
late genes related to differentiation, cytoskeletal maintenance, and mi-
tochondrial function; this attenuates their therapeutic efficacy against
fibrotic tissue [29].
Our study demonstrated that transplantation of MSCs+PE into CIM
muscle can activate phagocytosis, followed by tissue repair. Specifically,
senescent MSCs+PE shift the dominant phenotype of macrophages
from anti-inflammatory to pro-inflammatory; subsequently, anti-
inflammatory macrophages became dominant again, resulting in tissue
repair. Most chronic inflammatory diseases have refractory fibrosis due
to the predominance of anti-inflammatory macrophages, and the con-
version from the anti-inflammatory to pro-inflammatory phenotype
may aid in removal of fibrosis or cancer-related cells [49]. Transplanta-
tion of MSCs+PE enhanced phagocytic activity by activating pro-
inflammatory macrophages, NK cells, and Gr-1hi neutrophils, followed
by a decrease in the abundance of pro-inflammatory macrophages
and NK cells and an increase in the potent suppressive activity of Gr-
1low immature myeloid cells against CD8+ T cells [50]. This might pro-
mote remodelling in this chronic myopathymodel, in which infiltration
by CD8+ cells is predominant [19]. CDKN2A-KO MSCs did not exhibit
these immune-activating effects even when cultured in PE-containing
medium. These results provide evidence that CDKN2A expression in
MSCs is essential for treatment of CIM by creation of a regenerative in-
flammatory state.
We used human MSCs to understand the cell-biological reaction
of human MSCs to human placental extracts. Certainly, the effect of
(and response to) xenotransplantation of MSCs may differ from
that of transplantation of allogenic or autogenic MSCs [51]. However,
Galleu et al. reported that the results of treating GvHD patients with
human MSCs were similar to those of treating a GvHD mouse model
with human MSCs, and that mouse inflammatory cytokines did not
activate immunomodulatory molecules (IDO, TSG-6 or PTSG2 [prosta-
glandin-endoperoxide synthase 2]) in human MSCs [6]. Therefore, in
order to evaluate the therapeutic potential of human MSCs for future
clinical therapeutic applications, we performed this study using
human MSCs.
This study highlights a new strategy for MSC treatment based on
senescence-induced regeneration. A further impact of our discovery is
that the pertinent senescent MSC population provides a powerful
therapeutic effect,mediated by the creation of a regenerative inflamma-
tory state, in amurine CIMmodel. Likemuscle tissue,most tissues in the
body contain residentmesenchymal cells and resident or infiltrated im-
mune cells; therefore, the principle underpinning this therapeutic
mechanism should be applicable to other chronic inflammatory
diseases. The intriguing potential of senescent MSCs may provide new
opportunities for the clinical application of these cells.
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